Editas Deal Opens Allergan's Eyes To CRISPR Opportunities
Editas' stock shot up 11% by mid-morning on March 14, after the gene therapy company announced a deal with Allergan worth $90m up front for "cool" CRISPR programs in ocular indications. However, the lead therapy included in the deal offers potentially limited profitability in a small orphan space.
You may also be interested in...
It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.